Clinical Trials
24 trialsNCT03975959 2026-06-04
PROMESSE
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Completed
NCT02465060 2026-06-03
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05417594 2026-06-02
CERTIS1
AstraZeneca
Phase 1/2 Recruiting
NCT04521686 2026-04-22
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT04025541 2025-04-02
ALCINA2
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Recruiting
NCT01638533 2025-02-07
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT05500508 2024-12-24
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
Phase 1/2 Terminated
NCT04752267 2024-05-24
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
University of Southern California
Phase EARLY_PHASE1 Completed
NCT04541225 2023-07-14
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Nuvation Bio Inc.
Phase 1 Terminated
NCT02854644 2022-06-01
ERISA
Centre Hospitalier Universitaire de Besancon
Phase NA Completed
NCT00967577 2022-02-02
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
Weill Medical College of Cornell University
Phase 1 Completed
NCT02713984 2020-03-19
A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Southwest Hospital, China
Phase 1/2 Withdrawn
NCT01801852 2016-01-28
Autologous Natural Killer T Cells Infusion for the Treatment of Cancer
Chinese PLA General Hospital
Phase NA Unknown
NCT01386580 2015-01-22
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
BBB-Therapeutics B.V.
Phase 1/2 Completed
NCT01131234 2014-12-23
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00030498 2013-01-16
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT00019019 2012-03-15
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00020579 2012-03-15
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00049296 2010-06-11
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00909558 2010-02-24
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
Envita Medical Center, Inc.
Phase 1 Suspended
NCT00379132 2009-03-31
131-I-TM-601 Study in Adults With Solid Tumors
TransMolecular
Phase 1 Completed
NCT00338026 2008-07-15
A Phase I Study of ECO-4601 in Patients With Advanced Cancer
Thallion Pharmaceuticals
Phase 1 Completed